Ulcerative Colitis - Pipeline Review, H2 2018

Ulcerative Colitis - Pipeline Review, H2 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2018, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 16, 41, 33, 56 and 16 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 1 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction 7
Ulcerative Colitis - Overview 8
Ulcerative Colitis - Therapeutics Development 9
Ulcerative Colitis - Therapeutics Assessment 31
Ulcerative Colitis - Companies Involved in Therapeutics Development 45
Ulcerative Colitis - Drug Profiles 88
Ulcerative Colitis - Dormant Projects 500
Ulcerative Colitis - Discontinued Products 508
Ulcerative Colitis - Product Development Milestones 510
Appendix 523

List Of Tables


Number of Products under Development for Ulcerative Colitis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Ulcerative Colitis - Pipeline by 4D Pharma PLC, H2 2018
Ulcerative Colitis - Pipeline by AbbVie Inc, H2 2018
Ulcerative Colitis - Pipeline by AbGenomics International Inc, H2 2018
Ulcerative Colitis - Pipeline by Abivax SA, H2 2018
Ulcerative Colitis - Pipeline by Adello Biologics LLC, H2 2018
Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H2 2018
Ulcerative Colitis - Pipeline by Allergan Plc, H2 2018
Ulcerative Colitis - Pipeline by Alpha Cancer Technologies Inc, H2 2018
Ulcerative Colitis - Pipeline by Alvotech Iceland, H2 2018
Ulcerative Colitis - Pipeline by Am-Pharma BV, H2 2018
Ulcerative Colitis - Pipeline by Amgen Inc, H2 2018
Ulcerative Colitis - Pipeline by Antibe Therapeutics Inc, H2 2018
Ulcerative Colitis - Pipeline by Aptevo Therapeutics Inc, H2 2018
Ulcerative Colitis - Pipeline by Arena Pharmaceuticals Inc, H2 2018
Ulcerative Colitis - Pipeline by Artelo Biosciences Inc, H2 2018
Ulcerative Colitis - Pipeline by Atlantic Bio Sci LLC, H2 2018
Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H2 2018
Ulcerative Colitis - Pipeline by Avexegen Therapeutics Inc, H2 2018
Ulcerative Colitis - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Co, H2 2018
Ulcerative Colitis - Pipeline by Celgene Corp, H2 2018
Ulcerative Colitis - Pipeline by Cellix Bio Pvt Ltd, H2 2018
Ulcerative Colitis - Pipeline by Celltrion Inc, H2 2018
Ulcerative Colitis - Pipeline by ChemoCentryx Inc, H2 2018
Ulcerative Colitis - Pipeline by ChironWells GmbH, H2 2018
Ulcerative Colitis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018
Ulcerative Colitis - Pipeline by Coherus BioSciences Inc, H2 2018
Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals NV, H2 2018
Ulcerative Colitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H2 2018
Ulcerative Colitis - Pipeline by EA Pharma Co Ltd, H2 2018
Ulcerative Colitis - Pipeline by Eli Lilly and Co, H2 2018
Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H2 2018
Ulcerative Colitis - Pipeline by enGene Inc, H2 2018
Ulcerative Colitis - Pipeline by Enterome Bioscience SA, H2 2018
Ulcerative Colitis - Pipeline by Evelo Biosciences Inc, H2 2018
Ulcerative Colitis - Pipeline by Ferring International Center SA, H2 2018
Ulcerative Colitis - Pipeline by Fresenius SE & Co KGaA, H2 2018
Ulcerative Colitis - Pipeline by Galapagos NV, H2 2018
Ulcerative Colitis - Pipeline by Genentech Inc, H2 2018

List Of Figures


Number of Products under Development for Ulcerative Colitis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Ulcerative Colitis - Pipeline Review, H2 2018

Ulcerative Colitis - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2018, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline

USD 2000 View Report

Ulcerative Colitis Global Clinical Trials Review, H2, 2018

Ulcerative Colitis Global Clinical Trials Review, H2, 2018Its clinical trial report, Ulcerative Colitis Global Clinical Trials Review, H2, 2018 provides an overview of Ulcerative Colitis clinical trials scenario. This report

USD 2500 View Report

Ulcerative Colitis Global Clinical Trials Review, H2, 2018

Ulcerative Colitis Global Clinical Trials Review, H2, 2018Its clinical trial report, Ulcerative Colitis Global Clinical Trials Review, H2, 2018 provides an overview of Ulcerative Colitis clinical trials scenario. This report

USD 2500 View Report

Enterocolitis - Pipeline Review, H2 2018

Enterocolitis - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Enterocolitis - Pipeline Review, H2 2018, provides an overview of the Enterocolitis (Gastrointestinal) pipeline landscape.Enterocolitis is an

USD 2000 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available